The EGFR L718Q mutation is an infrequent mechanism of osimertinib resistance and its role in therapeutic application requires further investigation.[8] Here, we report 2 cases of advanced NSCLC patients with concomitant EGFR L858R/L718Q mutations after osimertinib resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.